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Abstract
Neurometabolic disorders are hereditary conditions mainly affect 
the function of the brain and the nervous system. The prevalence of 
these disorders is 1 in 1,000 live births. Such disorders, at different 
ages, could manifest as sepsis, hypoglycemia, and other neurologic 
disorders. Having similar manifestations leads to delayed diagnosis 
of neurometabolic disorders. A number of neurometabolic disorders 
have known treatments; however, to prevent long-term complications 
the key factors are early diagnosis and treatment. Although a large 
number of neurometabolic diseases have no treatment or cure, the 
correct and on-time diagnosis before death is important for parents 
to have plans for prenatal diagnosis. Different diagnostic procedures 
could be offered to parents, enzymatic procedures, and determining 
metabolites in plasma, urine, and CSF, and molecular genetic 
diagnosis. Molecular genetic diagnostic procedures are expensive 
and could not be offered to all parents. Therefore, we aimed to 
design algorithms to diagnose neurometabolic disorders according to 
some frequent and characteristic signs and symptoms. By designing 
these algorithms and using them properly, we could offer diagnostic 
enzymatic panels. These enzymatic panels are inexpensive; thereby 
reducing the financial burden on the parents. Also, having an early 
diagnosis according to these panels could lead to offering more 
accurate and less expensive molecular genetic tests.
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Introduction
Neurometabolic diseases are a group of disorders 
mainly affect the brain and the nervous system. 
These diseases could present in all periods of life 
from the neonatal period to adult life. A number 
of neurometabolic disorders may be present after a 
period of normal growth and development. These 
disorders have different manifestations at different 
ages. The crude prevalence of these disorders is 1 
in 1,000 live births. (1)
Neurometabolic diseases are divided into 3 main 
categories. 
1. Neurometabolic diseases mainly cause toxicity 
of tissues.
2. Neurometabolic diseases mainly cause defective 
energy production.
3. Neurometabolic diseases mainly cause defective 
metabolism of complex molecules.
A number of neurometabolic diseases have definite 
treatment; however, to prevent devastating and 
longterm complications, the key prognostic factors 
are early diagnosis and treatment. To diagnose 
these disorders, in addition to a high index of 
clinical suspicion, the clinicians who deal with 
these disorders need to confirm the diagnosis using 
sophisticated genetic tests. However, genetic tests 
usually are delayed and expensive; therefore, many 
of these genetic tests could not be offered to parents. 
According to a number of signs and symptoms, 
clinicians could request a number of enzymatic tests 
from plasma, urine, and cerebrospinal fluid (CSF) 
that always are confirmatory. These enzymatic tests 
are also inexpensive compared to genetic tests. In 
this review, we aimed to design simple algorithms 
using several characteristic signs and symptoms. 
According to these algorithms, we could propose 
diagnostic enzymatic panels for early diagnosis in 
different groups of neurometabolic disorders. In 
every section, we begin with a characteristic sign 
or symptom. 
1. Findings in neurometabolic diseases that could 
be approached efficiently
1.1. Cherry red spot
Cherry red spot is a reddish area at the center of 
macula surrounded by retinal opacification. This 
finding could be detected in different neurometabolic 
disorders that affect the macular area (Figure 1). 
Table 1 shows these neurometabolic disorders 
and the involved enzymes. (2-23) According to 
this table and algorithm 1, enzyme measurements 
could be requested for early diagnosis. (3)
Figure 1. Cherry-red spot at fundoscopy
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Table 1. Neurometabolic disorders with cherry-red spot and the involved enzyme
Neurometabolic disease Defective enzyme
Tay-Sachs Hexosaminidase A
Sandhoff Hexosaminidase A and B
GM2 activator deficiency Is not available
GM1 gangliosidosis Beta-galactosidase
Niemann-pick type A Acid sphingomyelinase
Metachromatic leukodystrophy (MLD) Arylsulfatase A
Multiple sulfatase deficiency (MSD) Arylsulfatase A, B, and C
Mucolipidosis type 1 (Sialidosis type II) Alpha-neuraminidase
Mucolipidosis type II (I-cell disease) N-acetyl glucoseamine phosphotransferase
Sialidosis type I Alpha-neuraminidase
Galactosialidosis Alpha-neuraminidase and BetaGalactosidase
Neuronal ceroid lipofuscinosis (NCL) Tripeptidyl peptidase 1
Mucopolysaccharidosis (MPS) type IV and VII N-acetylgalactosamine-6-sulfate/beta galactosidase 
(MPS4A/4B) and beta glucuronidase
Infantile free sialic acid storage disease (Severe form of 
Salla disease)
Increased free sialic acid in serum and urine and 
intracellular accumulation of free sialic acid in cultured 
fibroblasts
Farber lipogranulomatosis Accumulation of ceramide in tissues and
cultured fibroblasts
When the clinicians approach a patient who 
has cherry-red spot they should seek to find 
dysmorphism, visceromegaly, or different kinds 
of seizures. As shown in algorithm 1, finding 
dysmorphism, visceromegaly, or different kinds of 
seizures could help clinicians to have diagnostic 
plans. Brain MRI could also be used to differentiate 
neurometabolic disorders that show cherry-red 
spot. (12, 14, 16, 19, 20)
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Algorithm 1. Diagnostic approach to neurometabolic disorders with a cherry-red spot.
Except for GM2 activator deficiency, the rest 
of neurometabolic diseases in table 1 could be 
diagnosed efficiently using enzyme measurement. 
To offer the appropriate enzymatic panel, table 1 
must be reviewed precisely.
1.2. Chronic subdural effusion and hematomas
Chronic subdural effusion and hematomas could be 
found in a number of neurometabolic disorders. The 
list of these neurometabolic disorders is not long 
and this finding could be approached effectively 
to differentiate these kinds of neurometabolic 
disorders (Figure 2). Table 2 shows these 
neurometabolic disorders and the main diagnostic 
procedures. (11, 24-31)
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Table 2. Neurometabolic disorders with chronic subdural effusion and the main diagnostic approach
Neurometabolic disease Diagnostic tests
Glutaric aciduria type 1 Urine organic acids (GC/MS*), Glutaryl Co dehydrogenase 
activity in cultured fibroblasts
Menkes disease Plasma copper and ceruloplasmin
D2 hydroxy glutaric aciduria Urine organic acids (GC/MS)
Pyruvate carboxylase deficiency Plasma levels of pyruvate, lactate, and pyruvate carboxylase 
in cultured lymphocytes and fibroblasts
Dihydropyrimidine dehydrogenase deficiency Not available
Biotinidase deficiency Serum biotinidase activity
*GC/MS; gas chromatography/mass spectrometry
Algorithm 2 shows the diagnostic approach to neurometabolic disorders with chronic subdural effusion and 
hematomas. 
Algorithm 2. Approach to neurometabolic disorders with chronic subdural effusion and hematomas.
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Table 3. Neurometabolic diseases with alopecia and global developmental delay
Neurometabolic disease Diagnostic approach
Hypothyroidism T4, TSH
Vit D dependent rickets and receptor 
abnormalities
25-OH-Vit D and 1, 25(OH)2 Vit D
Biotinidase deficiency Biotinidase activity
Multiple carboxylase deficiency Biotinidase, Acetyl-CoA carboxylase, Pyruvate carboxylase, 
MethylcrotonylCo A Carboxylase, Propionyl Co A Carboxylase
1.3.  Alopecia and global developmental delay
A number of neurometabolic disorders could 
manifest with alopecia as a definitive sign in 
addition to global developmental delay. (30) 
Many of these have curative treatment; therefore, 
early diagnosis is mandatory to prevent longterm 
complications. Table 3 shows these neurometabolic 
disorders and their diagnostic approach. (5, 11, 15, 
30, 32)
Algorithm 3 shows the diagnostic approach to neurometabolic disorders with alopecia and global developmental delay. 
Algorithm 3. Approach to neurometabolic disorders with alopecia and global developmental delay.
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As shown in algorithm 3, in every patient with alopecia and global delay, we need to rule out hypothyroidism 
and Vit D-dependent rickets, then all we need are urine organic acid analysis using GC/MS and biotinidase 
activity. (29, 30)
1.4. Extensive and long-lasting Mongolian spots (diffuse melanocytosis)
Mongolian spots are congenital dermal melanocytoses that could normally be found on the back and 
the buttock regions in neonates. They disappear shortly after birth; however, when they are diffuse and 
extensively involve the skin, clinicians must consider a number of neurometabolic diseases (Figure 2). (17, 
33) 
Figure 2. Extensive Mongolian spot
 
Table 4. Neurometabolic disease with extensive Mongolian spots
Neurometabolic disease Enzyme
GM1 gangliosidosis Beta-galactosidase
Mucopolysaccharidosis (MPS) I Alpha L iduronidase
MPS II Iduronate 2 sulfatase
Niemann pick type A (NP A) Alpha mannosidase
α-mannosidosis Alpha-mannosidase
Mucolipidosis type I Alpha-Neuraminidase
Mucolipidosis type II N-Acetylglucosamine phosphotransferase
Table 4 shows the neurometabolic diseases with extensive Mongolian spots and the involved enzymes.
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Algorithm 4. Diagnostic approach to neonates and infants with extensive Mongolian spots.
Algorithm 4 shows the diagnostic approach to neonates and infants with extensive Mongolian spots.
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As has been shown in algorithm 4, to approach 
extensive Mongolian spots, clinicians should 
seek other findings such as dysmorphism and 
corneal opacity. The brain MRI could also help 
to differentiate neurometabolic diseases with 
extensive Mongolian spots. 
In the rest of this paper, we review the diagnostic 
approach to a number of laboratory and imaging 
findings that are characteristic of neurometabolic 
disorders.
2. Laboratory and imaging findings in 
neurometabolic disorders
2.1. Hyperammonemia
Ammonia is the endproduct of amino acids’ 
catabolism, and its abnormal high levels are toxic 
to the brain and the nervous system. To excrete 
ammonia, mammals use the urea cycle. The urea 
cycle is a complex cycle that needs more than five 
key enzymes to work efficiently and to transform 
produced ammonia to less toxic metabolites 
in the body. Measurement of ammonia level is 
mandatory in every patient with encephalopathy 
who might suffer from neurometabolic disorders. 
Neonates with hyperammonemia could present 
with progressive lethargy, vomiting, hypotonia, 
and seizures mainly after feeding. In older infants 
and children, hyperammonemia could present with 
ataxia, decreased consciousness, agitation, and 
irritability finally, might lead to coma. In all patients 
with unexplained encephalopathy, serum ammonia 
should be measured as soon as possible. Table 5 
shows the main causes of hyperammonemia and 
the involved enzymes. (1, 11, 27, 34)
Table 5. Neurometabolic disorders with hyperammonemia and the involved enzymes
Neurometabolic disorder Enzyme
Urea cycle defects Carbamyl phosphate synthetase (CPS) deficiency, Ornithine transcarbamylase 
(OTC) deficiency, Argininosuccinate synthetase (AS) deficiency, 
Argininosuccinate lyase (AL) deficiency, Arginase deficiency, Nacetyl 
glutamate synthetase deficiency
Organic acidemias Propionic academia, Methylmalonic academia, Isovaleric academia, Beta-
ketothiolase deficiency, Multiple carboxylase deficiency, Glutaric aciduria 
type II, 3-hydroxy -3-methylglutaric aciduria
Fatty acid oxidation disorders Long Chain Acyl CoA Dehydrogenase Deficiency (LCAD)
Medium Chain Acyl CoA Dehydrogenase Deficiency (MCAD)
Other etiologies of hyperammonemia are 
pyruvate dehydrogenase deficiency, lysinuric 
protein intolerance (LPI), Hyperammonemia-
Hyperornithinemi Homocitrullinemia syndrome 
(HHH), transient hyperammonemia of neonate, 
and congenital hyperinsulinism hyperammonemia. 
Algorithm 5 shows the diagnostic approach in 
patients with hyperammonemia. 
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Algorithm 5. Diagnostic approach in patients with hyperammonemia.
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In conclusion
In this short review, we showed that many 
neurometabolic disorders could be simply 
diagnosed by having a diagnostic plan after 
finding cherry-red spot, alopecia and global 
delay, and extensive Mongolian spot in the 
neurologic examination of the patient. We also 
Hypertyrosinemia
Tyrosine is the precursor for a bunch of neurotransmitters 
such as dopamine, norepinephrine, and epinephrine. It 
is also found in the structure of thyroxin and melanin. 
A number of congenital and acquired disorders cause 
hypertyrosinemia such as medications (amiodarone), 
liver dysfunction, hypothyroidism, high protein diet, 
and neurometabolic disorders. Algorithm 6 shows the 
diagnostic approach to a patient with hypertyrosinemia. 
(32)
Algorithm 6. Diagnostic approach to a patient with hypertyrosinemia.
showed diagnostic algorithms in patients with 
hyperammonemia, hypertyrosinemia, bilateral 
striatal necrosis. By using these algorithms, almost 
all clinicians could precisely approach to different 
kinds of neurometabolic disorders and request 
inexpensive enzymatic panels to administer 
early treatment. Using these algorithms also help 
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clinicians dealing with prenatal consults with 
parents. 
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